• Corpus ID: 25258808

Malignancies after rituximab treatment: just coincidence or more?

@article{Aksoy2011MalignanciesAR,
  title={Malignancies after rituximab treatment: just coincidence or more?},
  author={Sercan Aksoy and Çağatay Arslan and Hakan Harputluoglu and Omer Dizdar and Kadri Altundağ},
  journal={Journal of B.U.ON. : official journal of the Balkan Union of Oncology},
  year={2011},
  volume={16 1},
  pages={
          112-5
        },
  url={https://api.semanticscholar.org/CorpusID:25258808}
}
Close monitoring for second malignancies, particularly skin tumors, in patients treated with rituximab is suggested, however, it is suggested that this issue should be evaluated in further studies.
View on PubMed
23 Citations
Background Citations
9

23 Citations

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Insight is provided into the changing pattern of S PM occurrence after the introduction of rituximab, which may elucidate the aetiology of SPMs and should guide future cancer surveillance efforts among DLBCL patients.

Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms

Evaluating the characteristics, incidence of secondary malignancies and outcomes in patients with indolent B-cell neoplasms after receiving FCR based regimen aimed to evaluate the impact of different disease and hematological parameters on the incidence ofsecondary malignancy.

Large-cell neuroendocrine cancer of the colon following rituximab-based lymphoma treatment.

A 58-year-old man was referred in June 1991 with rectal bleeding for a colonoscopy that showed a sigmoid adenocarcinoma, which resulted in a large cell neuroendocrine carcinoma invading through the colonic wall and involving seven of 14 regional lymph nodes and the liver.

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

Rituximab is both safe and effective for the treatment of acquired angioedema with C1-inhibitor deficiency and antiphospholipid syndrome, autoimmune hepatitis, IgA nephropathy, inflammatory myositis, primary-progressive multiple sclerosis, systemic lupus erythematosus, and ulcerative colitis.

Secondary leiomosarcoma after treatment of diffuse large B cell lymphoma in a patient : a case report and literature review

A case of leiomyosarcoma in a 70-year-old Chinese man, diagnosed with diffuse large B cell lymphoma and accepted chemotherapy seven years ago, is discussed, and the risk of secondary tumor and reassessment of disease are discussed.

Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.

Rituximab is well tolerated among young people and is associated with few serious adverse events, but infections are common, corresponding to a prolonged period of B cell count recovery often lasting for longer than a year.

Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia

Two rare cases of MF concurring with diffuse large B cell lymphoma and acute myeloid leukemia (myeloid lineage) in two otherwise healthy elderly patients are reported.

Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials

This review highlights recent studies, mainly randomized controlled trials of rituximab for SSNS, including complicated and uncomplicated forms of FRNS or SDNS in children, and discusses the effects of these studies on the management of patients suffering from these conditions.

HERPES VIRUS, HUMAN PAPILLOMA VIRUS AND POLYOMAVIRUS INFECTION IN PATIENTS UNDERGOING BIOLOGICAL THERAPY

This review focuses on the risk of reactivation associated with biological therapy in patients with autoimmune diseases and underlying herpes virus, human papilloma virus and polyomavirus infections.

Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases

Rituximab had an acceptable safety profile in study patients, however, there must be certain cautions regarding the use of the medication for the elderly or patients with a compromised immune system.